The Association Between Viral Infections and Co-stimulatory Gene Polymorphisms in Kidney Transplant Outcomes

Ahmad Niknam,1 Mohammad Hossein Karimi,1,∗ Ramin Yaghobi,1 Bita Geramizadeh,1 Jamshid Roozbeh,1 Mehdi Salehipour,1 and Mahdiyar Iravani1

1Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran
∗Corresponding author: Mohammad Hossein Karimi, Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, IR Iran. Tel: +98-7136473954, Fax: +98-7136473954, E-mail: Karimimh@sums.ac.ir

Received 2015 July 07; Revised 2015 October 26; Accepted 2015 November 28.

Abstract

Background: The surveillance of kidney transplant patients depends on function of different immunologic markers like co-stimulatory molecules. These molecules may also be associated with post kidney transplant viral related outcomes.

Objectives: The aim of this study was to investigate the possible associations between co-stimulatory molecule gene polymorphisms and viral infections in kidney transplant patients.

Patients and Methods: In total, 172 kidney transplant patients were included in this study. Single nucleotide polymorphisms in loci of co-stimulatory molecules including: PDCD.1, CD28, CTLA4 and ICOS, were analyzed in the studied patients by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) methods. Active Cytomegalovirus (CMV) infection and history of hepatitis C virus (HCV) infection were analyzed in each kidney transplant patient using the CMV antigenemia kit and HCV antibody assay, according to the manufacturer's instructions.

Results: CMV active infection was found in 31 of 172 (18.02%) kidney transplant patients. HCV infection was only found in two of the 172 (1.16%) studied patients. Significant associations were found between TT and TC genotypes of CTLA4 -1722T/C and T allele with acute rejection in CMV infected kidney transplant patients. A significant association was also found between the T allele of CD28 +17 C/T genetic polymorphism and acute rejection in CMV infected kidney transplant patients. Significantly higher frequency of AA genotype and A allele of CTLA4 +49AG polymorphism were found in CMV infected female patients. Also a significantly higher frequency of GG genotype and G allele of PDCD-1.3A/G polymorphisms were found in CMV infected female patients.

Conclusions: Based on these results, CTLA4 and CD28 genetic polymorphisms, which regulate T-cell activation, can influence active CMV infection in kidney transplant patients. These results should be confirmed by further investigations.

Keywords: Costimulatory Molecules, Hepatitis C Virus, Kidney Transplantation, Cytomegalovirus

1. Background

Cytomegalovirus (CMV) infection is a frequent viral complication that occurs early post-kidney transplantation, and has been associated with increased graft rejection, morbidity and mortality (1, 2). It latently persists in the kidney and reactivates under immunosuppressive conditions, and causes direct and indirect clinical effects post-transplantation (2, 3). The nature of the specific immunologic defects predisposing kidney transplant patients to CMV infection and disease has also been partially elucidated (3). CMV may have substantial impact on host immune responses. Following infection, CMV infiltrates the cell and produces immediate-early antigens that regulate DNA production. During the ensuing 6 to 24 hours, CMV produces late antigens that direct nucleocapsid protein production. It also causes up regulation of IL-2 (IL-2) and can prevent the inhibition of IL-2 gene production by cyclosporine (4). CMV also down regulates MHC-I molecules on the surface of infected cells to evade host immune recognition (4). On the other hand, hepatitis C virus (HCV) is a well-known agent of acute and especially chronic liver diseases (5). HCV infection has also been established as an important factor in reducing graft and patient survival post-kidney transplantation (6-10).

Successful acceptance of the transplanted kidney requires proper balance in immune responses with minimal inflammatory and immunological allograft damages influenced by viral infections. Both antigen-specific and non-specific co-stimulatory signals are necessary for increasing the duration of graft surveillance and control of virus related clinical outcomes post-transplantation (11,
Therefore, in the past few years, study of the determinative role of T cell co-stimulatory activator and inhibitory pathways was focused in transplant immunology (13). The co-stimulatory molecules include the CD28 family, which contains three closely related proteins, CD28, cytotoxic T-lymphocyte associated protein 4 (CTLA4) and inducible T cell costimulator (ICOS), and also the more distantly related programmed cell death 1 (PDCD1) (14). Their ligands expressed on antigen presenting cells are members of the B7 family (15, 16). The encoding genes of CD28, CTLA4, ICOS and PDCD1 in human are localized on chromosome 2. The CD28, CTLA4 and ICOS genes are closely linked at 2q33.3 (17, 18). The CD28 and ICOS have been widely recognized as the major positive co-stimulation pathways for T cell activation and play a central role in immune responses against viruses and graft rejection (19). On the other hand, CTLA4 and PDCD1 play fundamental roles in controlling T cell reactivity to self-antigens via transmission of inhibitory signal to T cells. They have important roles in maintaining tolerance to self-antigens as a negative regulator of T cell activation in transplant patients (20).

Several polymorphisms take part in co-stimulatory molecules and affect regulation of activator and inhibitory functions of these proteins in transplant patients (21). Recent studies reported associations between co-stimulatory molecule gene polymorphisms with CMV- and HCV-related clinical outcomes in transplant patients (22, 23). Furthermore, CTLA4 gene polymorphisms have serious effects on a variety of clinical courses accompanied by CMV infection (23, 24). Over expression of PDCD-1 increased by gene polymorphisms in HCV and CMV specific CD8–T cells, has been shown to diminish their antiviral abilities (25-27).

Haplotype-tagging single nucleotide polymorphisms (SNPs) of CTLA4 at position +49 in exon 1 and in position -318 of promoter were examined in individuals treated for chronic HCV (28). The +49G allele alone and in a haplotype with -318C was associated with an increased frequency of sustained HCV response to alpha interferon and ribavirin (28, 29). Also, associations between co-stimulatory molecule gene polymorphisms with kidney graft surveillance were reported. One cohort study included 141 kidney recipients and 229 healthy subjects to examine the distribution of genotypes and allele frequencies of CTLA4 and CD28 genes (30, 31). In another study, 325 Korean kidney recipients were examined to define the distribution of genotypes and allele frequencies of CTLA4 gene polymorphisms associated with susceptibility to acute and late acute rejection episodes (32).

2. Objectives

Based on these earlier reports, the possible associations between CTLA4, PD-1, ICOS, and CD28 co-stimulatory molecule gene polymorphisms with viral infections were evaluated in kidney transplant patients.

3. Patients and Methods

3.1. Patients

In this study a total of 172 patients, who had undergone kidney transplantation at the transplant ward at Namazi hospital, affiliated to the Shiraz University of Medical Sciences, Shiraz, Iran, were consecutively enrolled between years 2006 and 2010. Patients were followed for the graft outcome and acute rejection episode(s) during at least six months post-transplantation. Transplant patients were divided into two studied groups according to the presence (AR group) or absence (non-AR control group) of acute rejection episodes. The ethics committee of Shiraz University of Medical Sciences approved the protocol, which conformed to the ethical guidelines of the 1975 Helsinki declaration, and a written informed consent was obtained from all subjects.

Donors were selected on the basis of ABO blood group compatibility and all the patients were negative for lymph cytotoxic cross matches. Rejection episodes were identified by an expert nephrology team, based on approved clinical diagnostic criteria, and invariability was confirmed by needle biopsy as well as elevated serum creatinine and blood urea nitrogen levels (33). The standard immunosuppressive regimen included cyclosporine (5 mg.kg initially, then a maintenance dose of 2 to 2.5 mg.kg; cyclosporine level was 50 to 150 ng/mL), prednisolone (120 mg/d initially, tapering to 10 mg/d), and mycophenolate mofetil (1000 mg twice daily). Acute rejection was initially treated with intravenous steroids and steroid-resistant rejection was treated with OKT3 monoclonal antibody.

3.2. Co-stimulatory Molecule Gene Polymorphisms

3.2.1. DNA Extraction Protocol

An EDTA-treated blood sample was collected from each kidney transplant patient anduffy coat and plasma were harvested from each of them and preserved at -80°C until use. Genomic DNA was extracted fromuffy coats using a QIAamp DNA mini kit (Qiagen, Germany), according to the manufacturer’s instructions.
3.2.2. Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) Protocols

The SNPs of co-stimulatory molecule genes including: four SNPs of CTLA4 gene (rs5742909, 162 bp upstream from the first nucleotide of the 5'-UTR, also known as -318 T/C, rs733618, -1722 T/C, rs4553808, -1661 A/G, an exonic SNP, rs231775, exon 1, Thr77Ala, also known as +49A/G), two SNPs from the PDCD1 gene (PDCD1.13 rs11568821 A/G intron SNP, PDCD1.19 rs2227982 C/T exon SNP), one SNP from the ICOS gene (1720 C/T) and one SNP from the CD28 (rs3116496, IVS3 +17 C/T) gene in chromosome 2q33-37. Polymerase chain reaction (PCR) cycles, the PCR thermocycling condition, primers and types of PCR for the co-stimulatory molecules are summarized in Table 1. Genetic polymorphisms for PDCD1.3 A/G, PDCD1.9 C/T, CD28 +17 C/T, CTLA4 -1722 T/C, -1661 A/G, -318 C/T, +49 A/G and ICOS +1720 C/T were analyzed using the PCR-RFLP method, as previously described (34-39).

3.3. Cytomegalovirus Antigenemia Assay

The CMV active infection was evaluated in EDTA-treated whole blood samples collected from kidney transplant patients by the CMV antigenemia method using CMV Brite Turbo kit (IQ Products, Groningen, The Netherlands), according to manufacturers’ instruction.

3.4. Hepatitis C Virus Enzyme Linked Immunosorbent Assay

The history of HCV infection was evaluated using the HCV antibody assay on plasma samples of kidney transplant patients by a third generation ELISA kit (DIAPRO, Italy), according to manufacturer’s instruction.

3.5. Statistical Analysis

Allele and genotype frequencies were calculated in studied kidney transplant patients by direct gene counting. Analysis was carried out using the statistical package for the social sciences (SPSS), version 16. The frequencies of the alleles and genotypes were compared in the two groups by chi-square test and Fisher’s exact test. Odds ratios and 95% confidence intervals (CIs) for relative risks were calculated. A probability value of P < 0.05 was considered as statistically significant and all the reported P values were two-tailed. The LD2SNPing program V 2.0 (http://www.bio.kuas.edu.tw/LD2SNPing) was used to estimate linkage disequilibrium (LD) and the results were evaluated using Arlequin V3.11.

4. Results

4.1. Patient’s Profile

The age range of kidney transplant patients was between 10 and 79 years old with mean of 38.28 ± 14.29. Overall, 113 of 172 (65.70%) kidney transplant recipients were male and 59 of 172 (34.30%) were female with a mean age of 38.28 ± 14.29 years old. Forty-five (26.16%) transplant patients were shown acute rejection and 127 (73.84%) patients did not experience acute rejection. Acute rejection was confirmed in 26 of 45 (57.8%) male and 19 of 45 (42.2%) female patients. Ninety-nine of 172 (57.6%) kidney transplant patients received transplant from cadaver and 73 (42.4 %) received transplant from living donors. Thirty-two of 99 (32.3%) who had received a transplant from cadaver and 13 of 73 (17.8%) with living donors experienced acute rejection.

4.2. Viruses and Kidney Transplantation

CMV active infection was found in 31 of 172 (18.02%) patients with an age range between 18 and 76 years with mean 36.90 ± 15.35. The 18 of 31 (58.06%) CMV infected patients were male and the rest (13 of 31; 41.94%) were female. Furthermore, 23 of 31 (74.19%) CMV infected patients received a graft from cadaver and 8 of 31 (25.81%) received a kidney from a living donor. Twenty of 31 (64.55%) CMV-infected patients experienced acute rejection and 11 of 31 (35.45%) CMV infected patients did not experience acute rejection. HCV infection was only found in two of 172 (1.16%) kidney transplant patients, who were male and received a graft from cadaver. One of the HCV-infected patients experienced acute rejection. No significant relationship was found between polymorphisms of co-stimulatory molecules and HCV infection in any kidney transplant patient.

4.3. Co-stimulatory Molecule Gene Polymorphisms and Cytomegalovirus Infection

Genotype frequencies of CD28, ICOS, CTLA4 and PDCD1 co-stimulatory genes in acute rejected and non-acute rejected kidney transplant patients with CMV infection are presented in Table 2. Significant associations were found between CTLA4 1722 TT and TC gene polymorphisms and also T allele with acute rejection in CMV-infected kidney transplant patients (P = 0.04, OR = undefined, 95% CI = undefined; P = 0.04, OR = 0.001, 95% CI = 0.001 - 2.24; P = 0.05, OR = undefined, 95% CI = undefined, respectively). A significant association was also found between the T allele of CD28 +17 C/T polymorphism with acute rejection in CMV-infected kidney transplant patients (P = 0.05, OR = 3.08, 95% CI = 0.84 - 11.84) and also significant associations were found between CD28 +17 C/T TT genetic polymorphism and non-acute rejection in CMV infected kidney transplant patients (P = 0.03, OR = 0.19, 95% CI = 0.03 - 1.18) (Table 2). On
| SNP             | Primer                        | Thermo Cycling Condition | Product Size                      | Method    |
|-----------------|-------------------------------|--------------------------|-----------------------------------|-----------|
| CTLA4, -1661A/G | F 5-CTAAGAGACATCGCTTCAGCATCTT-3 | 1 cycle: 95°C 5 min; 35 cycles: 95°C 30 sec, 59°C 60 sec, 72°C 60 sec; 1 cycle: 72°C 7 min | A allele: 119,147 bp; G allele: 486 bp | MseI based RFLP |
|                 | R 5-TTGGTGTGATGCACAGAAGCCCTTTTT-3 |                          |                                   |           |
| CTLA4, -318T/C  | F 5-AAATGAATTGGACCTGGATGG-3    | 1 cycle: 94°C 4 min; 30 cycles: 94°C 60 sec, 57°C 60 sec, 72°C 60 sec; 1 cycle: 72°C 5 min | T allele: 96+130 bp; C allele: 21 + 226 bp | MseI based RFLP |
|                 | R 5-TTACGAGAAGGGAAGCCGTG-3     |                          |                                   |           |
| CTLA4, +49A/G   | F 5-GCTCTACTCTCGTGACTCTC-3     | 1 cycle: 95°C 4 min; 30 cycles: 94°C 60 sec, 58°C 30 sec, 72°C 30 sec; 1 cycle: 72°C 7 min | A allele: 162 bp; G allele: 88,78 bp | BbvI based RFLP |
|                 | R 5-AGTCTCATCTACCTTTGAGAT-3    |                          |                                   |           |
| CTLA4, -1722T/C | F 5-CTAAGAGACATCGCTTCAGCATCTT-3 | 1 cycle: 95°C 5 min; 30 cycles: 95°C 60 sec, 62°C 60 sec, 72°C 60 sec; 1 cycle: 72°C 5 min | T allele: 486 bp; C allele: 216,270 bp | BbvI based RFLP |
|                 | R 5-TTGGTGTGATGCACAGAAGCCCTTTTT-3 |                          |                                   |           |
| CD28, +17C/T    | F 5-TTTTCTGGGTAAGAGAAGCCGACG-3 | 1 cycle: 95°C 5 min; 30 cycles: 95°C 60 sec, 58°C 60 sec, 72°C 60 sec; 1 cycle: 72°C 5 min | C allele: 147 bp; T allele: 22,125 bp | Eco47III based RFLP |
|                 | R 5-GAACCCTAAGACATGGG-3        |                          |                                   |           |
| PD.1.3, -7625T/C| F 5-GGACAGCTCAGAAGCTGAAGACG-3  | 1 cycle: 94°C 5 min; 30 cycles: 94°C 60 sec, 55.5°C 60 sec, 72°C 60 sec; 1 cycle: 72°C 5 min | T allele: 174,234 bp; C allele: 174,89,145 bp | Bpu10I based RFLP |
|                 | R 5-AGGTCTGAGAACACTCTG-3       |                          |                                   |           |
| PD.1, -7146A/G  | F 5-CCCAGGCGAGCAACCTCTACA-3    | 1 cycle: 95°C 4 min; 30 cycles: 95°C 60 sec, 55.5°C 60 sec, 72°C 60 sec; 1 cycle: 72°C 5 min | G allele: 180 bp; A allele: 57,323 bp | PstI based RFLP |
|                 | R 5-GAGGCGAGGCGAGGACAT-3       |                          |                                   |           |
| ICOS, 1720 C/T  | F 5-CTAAGAGACATTTGATGCCTTTCTT-3 | 1 cycle: 95°C 5 min; 30 cycles: 95°C 60 sec, 58°C 60 sec, 72°C 60 sec; 1 cycle: 72°C 5 min | C allele: 824 bp; T allele: 304,520 bp | NcoI based RFLP |
|                 | R 5-GTACCTTTCAACAATCATATC-3    |                          |                                   |           |

On the other hand, genotype frequencies of CD28, ICOS1720, CTLA4 and PD.1 co-stimulatory molecules between male and female kidney transplant patients with CMV infection are presented in Table 2. A significantly higher frequency of CTLA4 49A/G AA genotype and A allele polymorphism were found in CMV infected female patients (P = 0.02, OR = 0.15, 95% CI = 0.02 - 1.05; P = 0.01, OR = 0.17, 95% CI = 0.02 - 0.93, respectively) and also a significantly higher frequency of PDCD43 GG genotype and G allele polymorphisms was found in CMV infected female patients (P = 0.02, OR = 0.00, 95% CI = 0.00 - 1.11; P = 0.005, OR = 0.00, 95% CI = 0.00 - 0.69, respectively) (Table 3).

Moreover, the frequency of CTLA4, PD.1, CD28 and ICOS genotypes and alleles in CMV infected and non-infected kidney transplant patients are presented in Table 3. The AA genotype and A allele of CTLA4 1661 A/G had a higher...
frequency in CMV non-infected female patients compared with CMV infected ones ($P = 0.04$ and $P = 0.02$ respectively). The G allele and GG genotype of PDCD-1.3 had higher frequency in CMV non-infected female patients ($P = 0.03$ and $P = 0.02$ respectively), (Table 3).

4.4. Linkage Disequilibrium Between Cytomegalovirus Infection and Costimulatory Molecules

A linkage disequilibrium was found in CMV infected patients between CTLA4 (+49) and PD-1 + 7625 and ICOS + 1720 CTLA4 (-1661) gene polymorphisms ($D' = 1.000$, $P < 0.000$), and between ICOS + 1720 and CTLA4 (-1661) and PD-1 + 7625 gene polymorphisms ($D' = 1.000$, $P < 0.000$), and also found between CTLA4 (-318) and CD28 gene polymorphisms ($D' = 0.796$, $P < 0.000$), (Figure 1).

4.5. Co-stimulatory Molecule Gene Polymorphisms and Risk Factors

The mean ages of the patients, who had experienced an acute rejection episode after three months of follow-up was 36.16 ± 12.97. A significant association was found in A+ blood group with higher frequency of CTLA4 1661 A/G and -318 C/T gene polymorphisms in transplant patients ($P = 0.05$ and $P = 0.02$, respectively). Also, a significant association was found between age and acute rejection in kidney transplant patients ($P = 0.04$).

5. Discussion

Patients with CMV appear to have reduced allograft survival (40). Whether this is a direct effect on the allograft or an indirect consequence of infection leading to acute tubular necrosis and cellular rejection has been disputed. A few studies have shown the presence of CMV inclusions in allograft tissue, confounding the association of CMV and transplant glomerulonephropathy (4, 41). The negative role of CMV infection in inducing acute and chronic kidney transplant outcomes remains controversial, yet several studies suggested an immune response-based association between CMV pathogenesis and allograft rejection (36, 42, 43). Regarding immune system tools, costimulatory molecules and their related gene polymorphisms may affect post-transplant virus-related outcomes (22, 23). Therefore, in this study the role of co-stimulatory molecules’ genetic polymorphisms that may have influenced viral pathogenesis were evaluated in kidney transplant patients. The CD28 and ICOS are major co-stimulatory molecules activate T cell related pathways and introduce immune responses yet CTLA4 and PDCD1 negatively regulate T cell reactivation against viral infections (19, 20). Several genetic polymorphisms that occurred in co-stimulatory molecules encourage or reduce inflammatory T cell-based immune responses in transplant patients (21).

The PDCD-1 was expressed increasingly in the viral infected population, especially in patients with symptomatic CMV disease (44). However, in healthy asymptomatic CMV-infected individuals, levels of PDCD-1 on CMV-specific CD8 T cells were low similar to HIV-infected individuals (26). The simultaneous role of anti-rejection therapy in up-regulation of PDCD-1 was ruled out in CMV infected patients (26). In our earlier reports significant associations were not found between PDCD-1 genetic polymorphisms with active CMV infections in the liver and also hematopoietic stem cell transplant patients (24, 45). Similarly, in this study also the G allele and GG genotype of PDCD-1.3 had significantly higher frequency in CMV non-infected female patients. The CTLA4 has an important role in immunologic homeostasis, as a negative regulator of T cell activation (46).

Earlier reports present different controversial associations between CTLA4 genetic polymorphisms and viral infections and transplant outcomes. In one study, higher frequencies of CTLA4 318 C/T CT genotype and C allele and AG genotype of CTLA4 +49 A/G was found in CMV infected acute rejected liver transplant patients (24). Patients receiving hematopoietic stem cell transplant (HSCT) from a donor with significant higher presentation of CTLA4 CT60 AA genotype compared with AG/GG genotypes experienced lower grades of acute Graft versus host disease (aGVHD), yet experienced early post-transplant CMV infection (47). In our earlier study, a significant association was also found between CTLA4 +49AG AA genotype and A allele, found in CMV infected female liver transplant patients. The outcome of HBV infection was reduced in patients with higher frequency of GG and CC genotypes of CTLA4 +49 A/G and 1722 T/C loci, respectively (29, 48).

Successful clearance of HCV infection during therapy appeared by reduction of CTLA4 levels, which was encouraged with higher presentation of GG and CC genotypes of CTLA4 +49 A/G and -318 C/T loci, respectively (28). These findings present the deterministic role of CTLA4 polymorphisms on control of T cell proliferation leading to recovery of patients from chronic viral hepatitis clinical complications. Similarly, in this report, a significantly higher frequency of CTLA4 1722 TT and TC genotypes and also T allele were found in acute rejected CMV infected kidney transplant patients. Also significantly higher presentation of CTLA4 49AG AA genotype and A allele were found in CMV infected female patients.

The CD28 was the first cell surface co-stimulatory protein, which was diagnosed with the ability to activate T cell proliferation and development (49, 50). The CD28 T cell
### Figure 1. Linkage Disequilibrium (LD) Plot of Co-stimulatory Molecule Polymorphisms in D’ Value in CMV Infected and Non-Infected Kidney Transplant Patients

|                | PD -1.9 + 7625C.T | PD -1.3 + 7146G.A | ICOS + 1720C.T | CTLA - 4 + 49A.G | CTLA - 4 - 318C.T | CTLA - 4 - 1661A.G | CD28 IVS3 + 17T.C |
|----------------|-------------------|-------------------|----------------|------------------|-------------------|-------------------|-------------------|
| P              | 0.074             | 0.144             | 0.926          | 0.000            | 0.000             | 0.022             | 0.061            |
| P              | 0.000             | 0.001             | 0.022          | 0.000            | 0.085             | 0.123             | 0.926            |
| P              | 0.006             | 0.000             | 0.182          | 0.000            | 0.426             | 1.000             | 0.000            |
| P              | 0.507             | 0.000             | 0.000          | 1.000            | 0.282             | 1.000             | 0.000            |
| P              | 0.000             | 0.000             | 1.000          | 0.354            | 0.123             | 0.031             | 0.000            |
| P              | 0.655             | 0.240             | 1.000          | 1.000            | 0.190             | 0.088             | 0.000            |
| D’             |                   |                   | 0.077          | 0.345            | 0.456             | 0.184             |                   |

D’ values are multiplied by 100, for example; 100 in some boxes means a D’ of 1. Dark color boxes are representative of high LD and light color boxes indicate low LD. The left upper boxes indicate P values of less than 0.05.

The activation pathway plays a key role in immune responses against viral infections and in graft rejection (50). In our earlier report significantly higher frequency of the C allele and CC genotype of the CD28+17C/T gene locus was found in hepatitis B virus (HBV) infected allogeneic HSCT patients (24). Similarly, in our other study significantly higher frequency of T allele and TT genotype of the CD28 +17 C/T locus was found in CMV infected allogeneic HSCT patients with aGVHD (45). On the other hand, Kusztal et al. did not found any association between CD28+17C/T genetic polymorphisms and acute rejection in kidney transplant patients (11). In another study, no association was found between acute kidney graft rejections with CD28+17C/T genetic polymorphisms (51).

In this study, significantly higher frequency of the T allele of CD28 +17 C/T genetic polymorphism was observed in acute rejected and CMV infected kidney transplant patients. The ICOS gene, which is one of the CD28 family is expressed in resting T cells and activates T cells and CD28 co-stimulatory molecules, enhanced by cytokines IL12 and IL23 (52). In an earlier study an association between ICOS gene polymorphism and rejection was presented in kidney transplant patients (42). However, in this study no significant associations were found between ICOS+1720 C/T genetic polymorphisms and CMV infection in kidney transplant patients. In conclusion, based on these findings, CTLA4 and CD28 genetic polymorphisms regulate T cell activation and influence active CMV infection in kidney transplant patients. This study had a small group of evaluated transplant patients, thus it is better to confirm these results by larger studies.
further investigations.

Acknowledgments

The authors thank the members of the transplant research center, Shiraz, Iran for their helpful guidance, facilities and financial support.

Footnote

Funding/Support: This study was financially supported using a grant from Shiraz University of Medical Sciences.

References

1. Erdbruegger U, Scheffner I, Mengel M, Schwarz A, Verhagen W, Haller H, et al. Impact of CMV infection on acute rejection and long-term renal allograft function: a systematic analysis in patients with protocol biopsies and indicated biopsies. Nephrol Dial Transplant. 2002;17(1):435–43. doi: 10.1093/ndt/fgf306. [PubMed: 12172490].

2. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34(4):904–7. doi: 10.1086/339339. [PubMed: 1194998].

3. Reisser P, Cathomas G, Attenhofer R, Tamm M, Thiel G. Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J Infect Dis. 1999;180(2):247–53. doi: 10.1086/314879. [PubMed: 10395836].

4. Brennan DC. Cytomegalovirus in renal transplantation. J Am Soc Nephrol. 2001;12(4):584–55. [PubMed: 11274248].

5. Chen SL, Morgan TR. The natural history of hepatitis C virus infection and disease in transplant recipients. Am J Transplant. 2005;5(12):2718–22. doi: 10.1111/j.1600-665X.2005.01117.x. [PubMed: 1634858].

6. Aroldi A, Lampertico P, Montagnino G, Lunghi G, Passerini P, Tocchi P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion during chronic infection but not after vaccination. J Virol. 2007;81(11):5819–28. doi: 10.1128/JVI.00024-07. [PubMed: 17376899].

7. Einollahi B, Pourfarziani V, Ahmadzad-Asl M, Davoudi F, Lessan-Moghadam S, et al. Impaired expression of the interleukin-7 receptor alpha chain (CD127) containing the CD28, CTLA4, and ICOS gene cluster: analysis by computational, comparative, and microarray approaches. Genomics. 2001;78(3):355–68. doi: 10.1006/geno.2001.6655. [PubMed: 11735222].

8. Andres PG, Howland KC, Nair A, Zhang W, Maier HE, et al. CTLA-4 polymorphisms and clinical outcomes of acute rejection after liver transplantation in Chinese recipients. Transplantation. 2002;74(7):972–81. doi: 10.1097/01.TP.0000422414.200204.20.34972.aid-tmm0072.30.0026. [PubMed: 12005555].

9. Andres PG, Howland KC, Nair A, Zhang W, Maier HE, et al. CTLA-4 polymorphisms and clinical outcomes of acute rejection after liver transplantation in Chinese recipients. Transplantation. 2002;74(7):972–81. doi: 10.1097/01.TP.0000422414.200204.20.34972.aid-tmm0072.30.0026. [PubMed: 12005555].

10. Andres PG, Howland KC, Nair A, Zhang W, Maier HE, et al. CTLA-4 polymorphisms and clinical outcomes of acute rejection after liver transplantation in Chinese recipients. Transplantation. 2002;74(7):972–81. doi: 10.1097/01.TP.0000422414.200204.20.34972.aid-tmm0072.30.0026. [PubMed: 12005555].

11. Kusztal M, Koscielska-Kasprzak K, Drulis-Fajdasz D, Magott-Asztalos E, Kusztal M, Koscielska-Kasprzak K, Drulis-Fajdasz D, Magott-Asztalos E, et al. Assembly and annotation of human chromosome 2q33 sequence containing the CD28, CTLA4, and ICOS gene cluster: analysis by computational, comparative, and microarray approaches. Genomics. 2001;78(3):355–68. doi: 10.1006/geno.2001.6655. [PubMed: 11735222].

12. Reisser P, Cathomas G, Attenhofer R, Tamm M, Thiel G. Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J Infect Dis. 1999;180(2):247–53. doi: 10.1086/314879. [PubMed: 10395836].

13. Erdbruegger U, Scheffner I, Mengel M, Schwarz A, Verhagen W, Haller H, et al. Impact of CMV infection on acute rejection and long-term renal allograft function: a systematic analysis in patients with protocol biopsies and indicated biopsies. Nephrol Dial Transplant. 2002;17(1):435–43. doi: 10.1093/ndt/fgf306. [PubMed: 12172490].

14. Bernard D, Hansen JD, Du Pasquier L, Lefranc MP, Benmansour A, Boudinot P. Costimulatory receptors in jawed vertebrates: conserved CD28, odd CTLA4 and multiple BTLA. Dev Comp Immunol. 2007;31(3):255–71. doi: 10.1016/j.dci.2006.06.003. [PubMed: 16928399].

15. Collins M, Ling V, Carreno BM. The B7 family of immune-regulatory ligands. Genome Biol. 2005;6(3):221. doi: 10.1186/gb-2005-6-3-221. [PubMed: 15960813].

16. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2(4):116–26. doi: 10.1038/nri727. [PubMed: 11908983].

17. Lalage-Puchitaloff M, Costello R, Cousez D, Simonetti J, Mannoni P, Mawas C, et al. Human CD28 and CTLA-4 Ig superfamily genes are located on chromosome 2 at bands q33-q34. Immunogenetics. 1999;51(4):199–201. [PubMed: 1056778].

18. Jing Z, Chen Y, Feng X, Xie H, Zhou L, Zheng S. Recipient cytotoxic T lymphocyte antigen 4 +49 single-nucleotide polymorphism is not associated with acute rejection after liver transplantation in Chinese population. Int J Med Sci. 2013;10(3):250–4. doi: 10.7553/jims.551L. [PubMed: 23172431].

19. Collins M, Ling V, Carreno BM. The B7 family of immune-regulatory ligands. Genome Biol. 2005;6(3):221. doi: 10.1186/gb-2005-6-3-221. [PubMed: 15960813].

20. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. T helper type 2 differentiation. J Virol. 2006;80(5):2053–6. doi: 10.1128/JVI.00024-06. [PubMed: 169031].

21. Douroudis K, Laine AP, Heinonen M, Hermann R, Lipponen K, Veijola R, et al. Association of CTLA4 with but not ICOS polymorphisms with type 1 diabetes in two populations with different disease rates. Hum Immunol. 2009;70(7):536–9. doi: 10.1016/j.humimm.2009.04.023. [PubMed: 1937678].

22. Perez-Garcia A, De la Camara R, Roman-Gomez J, Jimenez-Velasco A, Encuentra M, Nieto B, et al. CTLA-4 polymorphisms and clinical outcomes of acute rejection after liver transplantation in Chinese recipients. Transplantation. 2002;74(7):972–81. doi: 10.1097/01.TP.0000422414.200204.20.34972.aid-tmm0072.30.0026. [PubMed: 12005555].

23. Zhang G, Liu Z, Duan S, Han Q, Li Z, Ly Y, et al. Association of polymorphisms of programmed cell death-1 gene with chronic hepatitis B virus infection. Hum Immunol. 2010;71(12):1209–13. doi: 10.1016/j.humimm.2010.08.014. [PubMed: 20837075].

24. Karimi MH, Motazedian M, Geramizadeh B, Qahghobian S, Yaghobi R, Abedi R, et al. Association of the Co-stimulatory Molecules Polymorphisms with CMV infection in Liver Transplant Recipients. Int J Organ Transplant Med. 2012;4(3):77–81. doi: 25013608.

25. Velu V, Kannanganat S, Ibegebue C, Chennareddi L, Villinger F, Freeman GJ, et al. Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8+ T cells during chronic infection but not after vaccination. J Virol. 2007;81(11):5819–28. doi: 10.1128/JVI.00024-07. [PubMed: 17376899].

Niknam A et al.

Jundishapur J Microbiol. 2016;9(8):e31338.
36. Ferreiros-Vidal I, Gomez-Reino JJ, Barros F, Carracedo A, Carreira P, Gonzalez-Escribano F, et al. Association of PDCD1 with susceptibility to systemic lupus erythematosus: evidence of population-specific differences. Ann Rheum Dis. 2008;67(6):753–60. doi: 10.1136/ard.2007.095781. [PubMed: 18048719].

37. Bardi R, et al. Genetic polymorphisms of immunoregulatory proteins and outcome of kidney transplantation. Transpl Immunol. 2008;20(4):152–6. doi: 10.1016/j.trim.2008.04.001. [PubMed: 18444671].

38. Wang L, Li D, Fu Z, Li H, Jiang W, Li D. Association of CTLA-4 gene polymorphisms with sporadic breast cancer in Chinese Han population. BMC Cancer. 2007;7:237. doi: 10.1186/1471-2407-7-237. [PubMed: 17825164].

39. Yousefipour G, Erfani N, Momtahan M, Ben Romdhane T, Bardi R, et al. Genetic polymorphisms of immunoregulatory proteins in acute renal allograft rejection. Transplant Proc. 2009;41(8):3305–7. doi: 10.1016/j.transproceed.2009.08.032. [PubMed: 19857736].

40. Hartmann A, Sagedal S, Hjelmesaeth J. The natural course of cytomegalovirus infection and disease in renal transplant recipients. Transplantation. 2006;82(2 Suppl):S5–7. doi: 10.1097/01.tp.0000230460.42558.b0. [PubMed: 16858268].

41. Birk PE, Chavers BM. Does cytomegalovirus cause glomerular injury in renal allograft recipients? J Am Soc Nephrol. 1997;8(1):1808-9. [PubMed: 9155085].

42. Burke GW 3rd, Kaufman DB, Mills J, Gaber AO, Johnson CP, Sunderland DE, et al. Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation: three-year results. Transplantation. 2004;77(8):1269–75. [PubMed: 1514097].

43. Haimila K, Turpeinen H, Alakulppi NS, Kyllonen LE, Salmela KT, Partanen J. Association of genetic variation in inducible costimulator gene with outcome of kidney transplantation. Transplantation. 2009;87(3):393–6. doi: 10.1097/TP.0b013e318192807a. [PubMed: 19202444].

44. La Rosa C, Limaye AP, Krishnan A, Longmate J, Diamond DJ. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis. 2007;195(5):633–44. doi: 10.1086/518307. [PubMed: 1726704].

45. Saadi MI, Yaghobi R, Karimi MH, Geramizadeh B, Ramzi M, Zakerinia M. Association of the costimulatory molecule gene polymorphisms and active cytomegalovirus infection in hematopoietic stem cell transplant patients. Mol Biol Rep. 2013;40(10):5833–42. doi: 10.1007/s11033-012-1669-x. [PubMed: 24057239].

46. Gavin M, Rudensky A. Control of immune homoeostasis by naturally arising regulatory CD4+ T cells. Curr Opin Immunol. 2003;15(6):690–6. [PubMed: 14630204].

47. Xiao H, Luo Y, Lai X, Fu S, Shi, Tan Y, et al. Genetic variations in T-cell activation and effector pathways modulate alloimmune responses after allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies. Haematologica. 2012;97(12):1804–12. doi: 10.3324/haematol.2012.056859. [PubMed: 22733023].

48. Idris ZM, Miswan N, Muhj M, Mohd TA, Kun FF, Noordin R. Association of CTLA4 gene polymorphisms with lymphatic filariasis in an East Malaysian population. Hum Immunol. 2018;79(2):167–72. doi: 10.1016/j.humimm.2017.11.007. [PubMed: 28157860].

49. June CH, Ledbetter JA, Linsley PS, Thompson CB. Role of the CD28 receptor in T-cell activation. Immunol Today. 1990;11(6):201–6. [PubMed: 2162180].

50. Turkla LA, Ledbetter JA, Lee K, June CH, Thompson CB. CD28 is an inducible T cell surface antigen that transduces a proliferative signal in CD4+ mature thymocytes. J Immunol. 1990;144(6):1564–53. [PubMed: 2155284].

51. Krichen H, Sfar I, Ben Abdallah T, Bardi R, Abderrahim E, Jendoubi-Ayed S. In: Kidney Transplantation - New Perspectives. Trzciensk M, editor. Rijeka: INTECH Open Access Publisher; 2011. pp. 111–15. doi: 10.5772/19552.

52. Wassink I, Vieira PL, Smits HH, Kingsbury GA, Coyle AJ, Kapsenberg ML, et al. ICOS expression by activated human Th cells is enhanced by IL-12 and IL-23: increased ICOS expression enhances the effector function of both Th1 and Th2 cells. J Immunol. 2004;173(3):779–86. [PubMed: 15265908].

8

Jundishapur J Microbiol. 2016;9(8):e31338.
Table 2. Genotype Frequencies of CD28, ICOS1720, CTLA-4 and PD1 Co-stimulatory Genes Between Male and Female Kidney Transplant Patients with CMV Infection\textsuperscript{a,b}

| SNP                  | Rejection \textsuperscript{a} | Non-Rejection \textsuperscript{a} | P Value \textsuperscript{b} | OR       | 95% CI                |
|----------------------|-------------------------------|-----------------------------------|-----------------------------|----------|-----------------------|
| **CTLA-4, -318 C/T** |                               |                                   |                             |          |                       |
| Genotypes            |                               |                                   |                             |          |                       |
| CC                   | 15 (75)                       | 8 (46.7)                          | 0.88                        | 1.13     | 0.16 - 7.83           |
| CT                   | 5 (25)                        | 3 (27.3)                          | 0.88                        | 0.89     | 0.13 - 6.39           |
| TT                   | 0 (0)                         | 0 (0)                             | Undefined                   | Undefined| Undefined             |
| Alleles              |                               |                                   |                             | 0.89     | 1.11                  |
| C                    | 35 (87.5)                     | 19 (87.5)                         |                             |          | 0.18 - 6.21           |
| T                    | 5 (12.5)                      | 3 (13.6)                          |                             |          |                       |
| **CTLA-4, +49 A/G**  |                               |                                   |                             |          |                       |
| Genotypes            |                               |                                   |                             |          |                       |
| AG                   | 6 (30)                        | 4 (36.4)                          | 0.71                        | 0.75     | 0.12 - 4.63           |
| AA                   | 13 (65)                       | 6 (17.6)                          | 0.56                        | 1.55     | 0.27 - 9.03           |
| GG                   | 1 (5)                         | 1 (54.5)                          | 0.65                        | 0.53     | 0.01 - 21.97          |
| Alleles              |                               |                                   |                             | 0.51     | 1.50                  |
| A                    | 32 (87.5)                     | 16 (72.7)                         |                             |          | 0.38 - 5.93           |
| G                    | 8 (12.5)                      | 6 (27.3)                          |                             |          |                       |
| **CTLA-4, -1661 A/G**|                               |                                   |                             |          |                       |
| Genotypes            |                               |                                   |                             |          |                       |
| GG                   | 1 (5)                         | 0 (0)                             | 0.45                        | Undefined| Undefined             |
| AA                   | 14 (70)                       | 7 (63.6)                          | 0.71                        | 1.33     | 0.22 - 8.25           |
| GA                   | 5 (25)                        | 4 (36.4)                          | 0.50                        | 0.58     | 0.09 - 3.73           |
| Alleles              |                               |                                   |                             | 0.94     | 1.05                  |
| A                    | 33 (82.5)                     | 18 (81.8)                         |                             |          | 0.22 - 4.80           |
| G                    | 7 (17.5)                      | 4 (18.2)                          |                             |          |                       |
| **CTLA-4, -1722 C/T**|                               |                                   |                             |          |                       |
| Genotypes            |                               |                                   |                             |          |                       |
| TT                   | 20 (100)                      | 9 (81.8)                          | 0.04 \textsuperscript{c}    | Undefined| Undefined             |
| TC                   | 0 (0)                         | 2 (38.8)                          | 0.04 \textsuperscript{c}    | 0.001    | 0.001 - 2.24          |
| CC                   | 0 (0)                         | 0 (0)                             | Undefined                   | Undefined| Undefined             |
| Alleles              |                               |                                   |                             | 0.05 \textsuperscript{c}   | Undefined|
| T                    | 40 (100)                      | 20 (90.9)                         |                             |          |                       |
| C                    | 0(0)                          | 2 (9.1)                           |                             |          |                       |
| **PDCD-1, 1.9T/C**   |                               |                                   |                             |          |                       |
| Genotypes            |                               |                                   |                             |          |                       |
| CC                   | 14 (70)                       | 10 (90.9)                         | 0.18                        | 0.23     | 0.01 - 2.63           |
| TC                   | 5 (25)                        | 1 (9.9)                           | 0.28                        | 3.33     | 0.28 - 87.48          |
| TT                   | 1(5)                          | 0 (0)                             | 0.45                        | Undefined| Undefined             |
| Alleles              |                               |                                   |                             | 0.34     | 4.45                  |
| T                    | 7 (17.5)                      | 1 (4.5)                           |                             |          | 0.48 - 103.32         |
| Genotypes | GG    | GA    | AA    | Alleles |
|-----------|-------|-------|-------|---------|
| Genotypes | 16 (80)| 2 (10)| 2 (10)| 0.88    |
|           | 9 (81.8)| 1 (9.1)| 1 (9.1)| 0.89    |
|           | 0.90 | 0.93 | 0.93 |         |
|           | 0.09 - 7.70 | 1.11 | 1.11 |         |
| Alleles   | G 34 (85) | A 6 (15) |       | 0.35 - 4.75 |
|           | 19 (84.4) | 3 (13.6) |       |         |

| Genotypes | CC    | TC    | TT    | Alleles |
|-----------|-------|-------|-------|---------|
| Genotypes | 4 (20)| 11 (55)| 5 (25)| 0.05 * |
|           | 1 (9.1)| 3 (27.3)| 7 (63.6)| 3.08 |
|           | 0.42 | 0.13 | 0.03 * | 0.84 - 11.84 |
| Alleles   | C 19 (47.5) | T 21 (52.5) |       |         |
|           | 5 (22.7) | 17 (77.5) |       |         |

| Genotypes | CT    | CC    | TT    | Alleles |
|-----------|-------|-------|-------|---------|
| Genotypes | 6 (10)| 13 (65)| 1(5)  | 0.86    |
|           | 4 (36.4)| 7 (63.6)| 0(0)  |         |
|           | 0.71 | 0.93 | 0.45 |       |
|           | 0.75 | 1.06 | Undefined |       |
| Alleles   | C 32 (80) | T 8 (20) |       | 0.19 - 3.94 |
|           | 18 (81.8) | 4 (88.2) |       |         |

Abbreviations: CI, confidence interval; OR, odds ratio; SNP, single nucleotide polymorphism.

*Values are expressed as No. (%).

*In genotypes, each P value is the result of comparing the corresponding row with the sum of other rows.
Table 3. The Genotypes and Allele Frequencies of CTLA4, PDL1, CD28 and ICOS Co-stimulatory Molecules Between CMV Infected and Non Infected Kidney Transplant Patients

| SNP             | CMV Infected Male | CMV Infected Female | CMV Infected Total | CMV Non-Infected Male | CMV Non-Infected Female | CMV Non-Infected Total | P value a,b,c | P value d | P value e,f |
|------------------|-------------------|---------------------|--------------------|-----------------------|-------------------------|------------------------|----------------------|----------|-----------|
| **CTLA4, 1661 A/G** |
| Genotypes       |                   |                     |                    |                       |                         |                        |                      |          |           |
| G    | 1 (5.5)           | 0 (0)               | 1 (3.2)            | 5 (5.3)               | 10 (7.1)                | 15 (7.1)               | 0.42             | 0.95     | 0.21      |
| A    | 11 (61.1)         | 11 (84.6)           | 22 (71)            | 57 (60)               | 25 (54.3)               | 82 (58.1)              | 0.18             | 0.91     | 0.14 f    |
| Alleles         |                   |                     |                    |                       |                         |                        |                      |          |           |
| G    | 6 (33.3)          | 2 (15.4)            | 8 (25.8)           | 31 (47.1)             | 16 (34.8)               | 47 (34.8)              | 0.33             | 0.99     | 0.07      |
| A    | 14 (77.8)         | 24 (92.3)           | 38 (100)           | 147 (77.4)            | 66 (71.7)               | 213 (75.5)             | 0.01             | 0.95     | 0.01      |
| **CTLA4, 1722 T/C** |
| Genotypes       |                   |                     |                    |                       |                         |                        |                      |          |           |
| T    | 16 (88.9)         | 13 (100)            | 29 (93.5)          | 85 (94.2)             | 42 (91.4)               | 127 (90.1)             | 0.40             | 0.94     | 0.27      |
| C    | 2 (11.1)          | 0 (0)               | 2 (6.5)            | 9 (9.5)               | 2 (4.3)                 | 11 (7.8)               | 0.79             | 0.82     | 0.44      |
| Alleles         |                   |                     |                    |                       |                         |                        |                      |          |           |
| T    | 34 (94.4)         | 28 (100)            | 62 (100)           | 179 (94.2)            | 86 (93.5)               | 265 (94)               | 0.38             | 0.95     | 0.00      |
| C    | 2 (5.6)           | 2 (7.7)             | 4 (6)              | 14 (5.8)              | 6 (6.5)                 | 20 (6)                 | 0.69             | 0.95     | 0.00      |
| **CTLA4, -318 C/T** |
| Genotypes       |                   |                     |                    |                       |                         |                        |                      |          |           |
| C    | 13 (72.2)         | 10 (76.9)           | 23 (74.2)          | 76 (96)               | 42 (96.4)               | 118 (96)               | 0.52             | 0.45     | 0.08      |
| T    | 5 (27.8)          | 3 (23.1)            | 8 (25.8)           | 18 (14.0)             | 8 (13.6)                | 26 (14)                | 0.25             | 0.82     | 0.44      |
| Alleles         |                   |                     |                    |                       |                         |                        |                      |          |           |
| C    | 31 (86.1)         | 23 (88.5)           | 54 (87.1)          | 168 (88.4)            | 80 (87)                 | 248 (87.9)             | 0.53             | 0.69     | 0.83      |
| T    | 5 (13.9)          | 3 (11.5)            | 8 (12.9)           | 22 (11.6)             | 12 (13)                 | 34 (12.1)              | 0.44             | 0.44     | 0.44      |
| **CTLA4, +49 A/G** |
| Genotypes       |                   |                     |                    |                       |                         |                        |                      |          |           |
| A    | 8 (44.4)          | 2 (15.4)            | 10 (32.2)          | 30 (31.6)             | 17 (37)                 | 47 (33.4)              | 0.50             | 0.28     | 0.14      |
| G    | 8 (44.4)          | 11 (84.6)           | 19 (61.3)          | 51 (53.7)             | 28 (60.0)               | 79 (56)                | 0.59             | 0.47     | 0.11      |
| Alleles         |                   |                     |                    |                       |                         |                        |                      |          |           |
| A    | 8 (44.4)          | 3 (16.7)            | 11 (66.7)          | 30 (61.1)             | 17 (34)                 | 47 (27.3)              | 0.44             | 0.73     | 0.12      |
| G    | 3 (16.7)          | 0 (0)               | 3 (16.7)           | 6 (12.8)              | 5 (10)                  | 11 (6)                 | 0.62             | 0.10     | 0.20      |
| **PDCD-1.3 A/G** |
| Genotypes       |                   |                     |                    |                       |                         |                        |                      |          |           |
| G    | 12 (66.6)         | 10 (76.9)           | 22 (74.2)          | 65 (84.4)             | 34 (72.9)               | 99 (76.4)              | 0.24             | 0.88     | 0.01 f    |
| A    | 6 (33.3)          | 3 (23.1)            | 9 (25.8)           | 21 (15.6)             | 8 (17.4)                | 29 (23.6)              | 0.47             | 0.61     | 0.10      |
| Alleles         |                   |                     |                    |                       |                         |                        |                      |          |           |
| G    | 14 (87.5)         | 24 (91.3)           | 38 (100)           | 116 (94.4)            | 56 (82.4)               | 172 (94)               | 0.46             | 0.40     | 0.12 f    |
| A    | 2 (12.5)          | 2 (8.7)             | 4 (10)             | 16 (5.6)              | 16 (17.6)               | 32 (16)                | 0.48             | 0.52     | 0.10      |
| **PDCD-1.9 C/T** |
| Genotypes       |                   |                     |                    |                       |                         |                        |                      |          |           |
| C    | 31 (93.3)         | 9 (60.2)            | 40 (91.5)          | 71 (94.7)             | 31 (71.7)               | 104 (73.7)             | 0.07             | 0.31     | 0.06      |
| T    | 3 (6.7)           | 5 (40)              | 8 (10)             | 8 (14.3)              | 13 (28.3)               | 21 (26.3)              | 0.53             | 0.31     | 0.34      |
| Alleles         |                   |                     |                    |                       |                         |                        |                      |          |           |
| C    | 19 (66.7)         | 20 (80.0)           | 39 (92.5)          | 85 (94.6)             | 74 (90.4)               | 259 (94.2)             | 0.27             | 0.12     | 0.09      |
| T    | 9 (33.3)          | 5 (20.0)            | 14 (7.5)           | 8 (14.4)              | 8 (9.6)                 | 30 (5.8)               | 0.30             | 0.09     | 0.09      |
| **CD28 +17 C/T** |
| Genotypes       |                   |                     |                    |                       |                         |                        |                      |          |           |
| C    | 13 (46.7)         | 21 (80.0)           | 34 (68.0)          | 54 (94.4)             | 34 (84.1)               | 88 (92.9)              | 0.46             | 0.27     | 0.09      |
| Genotypes | CC | TC | TT | C | T | Alleles | ICOS, 1720 C/T |
|-----------|----|----|----|---|---|---------|----------------|
| CC        | 4  | 1  | 1  | 15 | 21 | 0.55    | 8 (9.8)        |
| TC        | 7  | 7  | 7  | 10 | 10 | 0.67    | 7 (44.4)       |
| TT        | 7  | 7  | 7  | 10 | 10 | 0.68    | 5 (33.3)       |
| Alleles   | C  | T  | C  | 0.52| 0.79| 0.54    | 0.61           |

| Genotypes | CT | CC | TT | C | T | Alleles |
|-----------|----|----|----|---|---|---------|
| CT        | 8  | 10 | 0  | 20 | 46 | 0.30    |
| CC        | 10 | 10 | 10 | 10 | 10 | 0.31    |
| TT        | 0  | 0  | 0  | 0  | 0  | 0.31    |
| Alleles   | C  | T  | C  | 0.52| 0.79| 0.54    |

Abbreviations: SNP, single nucleotide polymorphism; CMV, Cytomegalovirus.

Values are expressed as No. (%).

In genotypes, each P value is the result of comparing the corresponding row with the sum of other rows.

P Value 1 = significant difference between total male and female CMV infected and non-infected kidney transplant patients.

P Value 2 = significant difference between male CMV infected and non-infected kidney transplant patients.

P Value 3 = significant difference between female CMV infected and non-infected kidney transplant patients.